News of Note—Seqirus, VBI and Altimmune

Newspapers
Approval of Fluad in the U.K. is among this week's news of note.

> The U.K.’s Medicines and Healthcare products Regulatory Agency has cleared Seqirus’ adjuvanted trivalent influenza vaccine Fluad for use in people aged 65 years or older, 20 years after it was made available in other European countries. PharmaTimes article

> The FDA has accepted VBI Vaccines’ investigational new drug application for VBI-1901, an immunotherapy targeting glioblastoma multiforme. Release

> Altimmune submitted an IND application for its intranasally administered recombinant flu vaccine candidate NasoVAX. Release